Confirmation of antidepressant potential of the selective β3 adrenoceptor agonist amibegron in an animal model of depression

Pharmacology Biochemistry and Behavior

Volumn 89, Issue 4, 2008, Pages 623-626

  Overstreet, David H ^a   Stemmelin, Jeanne ^b   Griebel, Guy ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b SANOFI   (France)

Author keywords

3 adrenergic receptor; Amibegron; Forced swim test; FSL rat model of depression

Indexed keywords

[[7 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO] 5,6,7,8 TETRAHYDRO 2 NAPHTHYL]OXY]ACETIC ACID ETHYL ESTER; DESIPRAMINE; FLUOXETINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; FLINDERS RESISTANT LINE RAT; FLINDERS SENSITIVE LINE RAT; FORCED SWIMMING TEST; IMMOBILIZATION; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; STRAIN DIFFERENCE; TREATMENT DURATION;

ADRENERGIC BETA-AGONISTS; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; MOTOR ACTIVITY; RATS; RECEPTORS, ADRENERGIC, BETA-3; SOCIAL BEHAVIOR; TETRAHYDRONAPHTHALENES;

ANIMALIA; RATTUS;

EID: 41949132109     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.02.020     Document Type: Article

References (32)

1. Bakalian M.J., and Fernstrom J.D. Effects of l-tryptophan and other amino acids on electroencephalographic sleep in the rat. Brain Res 528 (1990) 300-307
2. Benca R.M., Overstreet D.H., Gilliland M.A., Russell D., Bergmann B.M., and Obermeyer W.H. Increased basal REM sleep but no difference in dark induction or light suppression of REM sleep in Flinders Rats with cholinergic supersensitivity. Neuropsychopharmacology 15 (1996) 45-51
3. Bianchetti A., and Manara L. In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical beta-adrenoceptors in rat colon. Br J Pharmacol 100 (1990) 831-839
4. Borsini F., and Meli A. Is the forced swim test a suitable model for revealing antidepressant activity?. Psychopharmacology 94 (1988) 147-160
5. Claustre Y., Leonetti M., Sarhan M., Santucci V., Bougault I., Desvignes C., et al. Effects of β3-adrenoceptor agonist SR58611A (amibegron) on serotonergic and noradrenergic transmission in the rodent: relevance to its antidepressant/anxiolytic-like profile. Program no. 170.15. Neuroscience Meeting Planner (2007), Society for Neuroscience, San Diego, CA
6. Consoli D., Leggio G.M., Mazzola C., Micale V., and Drago F. Behavioral effects of the β3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?. Eur J Pharmacol 573 (2007) 139-147
7. Cryan J.F., Valentino R.J., and Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced-swimming test. Neurosci Biobehav Rev 29 (2005) 547-569
8. File S.F., and Seth P. A review of 25 years of the social interaction test. Eur J Pharmacol 463 (2003) 35-53
9. Hasegawa S., Nishi K., Watanabe A., Overstreet D.H., and Diksic M. Brain 5-HT synthesis in the Flinders Sensitive Line rat model of depression: an autoradiographic study. Neurochem Int 48 (2006) 358-366 [Jan 18 Electronic publication PMID: 16377459]
10. Himmelhoch J., Levine J., and Gershon S. Historical overview of the relationship between anxiety disorders and affective disorders. Depress Anxiety 14 (2001) 53-66
11. Holoubek G., Noldner M., Treiber K., and Muller W.E. Effect of chronic antidepressant treatment on beta-receptor coupled signal transduction cascade. Which effect matters most?. Pharmacopsychiatry 37 suppl 2 (2004) S113-S119
12. Lenard N.R., Gettys T.W., and Dunn A.J. Activation of beta2- and beta3-adrenergic receptors increases brain tryptophan. J Pharmacol Exp Ther 305 (2003) 653-659
13. Manara L., and Bianchetti A. Further heterogeneity of the beta-adrenoceptor. The phenylethanolaminotetralines: new selective agonists for atypical beta-adrenoceptors. Trends Pharmacol Sci 11 (1990) 229-230
14. Millan M. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 110 (2006) 135-370
15. Overstreet D.H. The Flinders Sensitive Line rats: a genetic animal model of depression. Neurosci Biobehav Rev 17 (1993) 51-68
16. Overstreet D.H. Behavioral characteristics of rat lines selected for differential hypothermic responses to cholinergic or serotonergic agonists. Behav Genet 32 (2002) 335-348
17. 1 receptor antagonist SSR125543 in an animal model of depression. Eur J Pharmacol 497 (2004) 49-53
18. Overstreet D.H., Pucilowski O., Rezvani A.H., and Janowsky D.S. Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression. Psychopharmacology 121 (1995) 27-37
19. Overstreet D.H., Keeney A., and Hogg S. Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression. Eur J Pharmacol 492 (2004) 195-201
20. Overstreet D.H., Friedman E.F., Mathe' A.M., and Yadid G. The Flinders Sensitive Line rat: a selectively bred putative animal model of depression. Neurosci Biobehav Rev 29 4-5 (2005) 739-759 [Epub 2005 Apr 22]
21. Porsolt R., Le Pichon, and Jalfre M. Depression. A new animal model sensitive to antidepressant treatments. Nature 266 (1977) 730-732
22. Pucilowski O., and Overstreet D.H. Effect of chronic antidepressant treatment on responses to apomorphine in selectively bred rat strains. Brain Res Bull 32 (1993) 471-475
23. Ressler K.J., and Nemeroff C.B. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12 (2000) 1098-1106
24. Schiller G.D., Daws L.C., Overstreet D.H., and Orbach J. Absence of anxiety in an animal model of depression with cholinergic supersensitivity. Brain Res Bull 26 (1991) 443-447
25. Schiller G.D., Pucilowski O., Wienicke C., and Overstreet D.H. Immobility-reducing effects of antidepressants in a genetic animal model of depression. Brain Res Bull 28 (1992) 821-823
26. Sharpley A.L., and Cowen P.J. Effect of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry 37 (1995) 85-98
27. Shiromani P.J., Overstreet D.H., Levy D., Goodrich C.A., Campbell S.S., and Gillin J.C. Increased REM sleep in rats selectively bred for cholinergic hyperactivity. Neuropsychopharmacology 1 (1988) 127-l33
28. Simiand J., Keane P.E., Guitard J., Langlois X., Gonalons N., Martin P., et al. Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical beta-adrenoceptors. Eur J Pharmacol 219 (1992) 193-201
29. Stemmelin J., Cohen C., Terranova J.P., Lopez-Grancha M., Pichat P., Bergis O., et al. Stimulation of the β3-adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology 33 (2008) 574-587 [Electronic publication 2007 Apr 25]
30. Strosberg A.D. Structure and function of the beta 3-adrenergic receptor. Annu Rev Pharmacol Toxicol 37 (1997) 421-450
31. Zangen A., Overstreet D.H., and Yadid G. High serotonin and 5-Hydroxyindoleacetic acid levels in limbic regions of a rat model of depression: normalization by chronic antidepressant treatment. J Neurochem 69 (1997) 2477-2483
32. Zangen A., Overstreet D.H., and Yadid Y. Increased catecholamine levels in specific brain regions of a rat model of depression: normalization by chronic antidepressant treatment. Brain Res 824 (1999) 243-250